BioPharmSignal logoBioPharmSignal

Biotech News

Xtant Medical Reports Fourth Quarter and Full-Year 2025 Financial Results

Xtant Medical (XTNT)Xtant MedicalEarnings

Full year 2025 revenue totals $133.9 million, an increase of 14% year-over-year Xtant delivers positive net income, adjusted EBITDA and operating cash flow Total cash of $17.3 million as of December 31, 2025 with an additional $10.5 million received subsequent to year end related to divestiture

Open original release

Related news

XTNTXtant Medical2026-03-25 12:00 EST

Xtant Medical to Announce Fourth Quarter and Full Year 2025 Financial Results on March 31, 2026

XTNTXtant Medical2026-05-13 11:00 EST

Xtant Medical Reports First Quarter 2026 Financial Results

XAIRBeyond Air2026-06-26 11:00 EST

Beyond Air® Reports Fourth Quarter and Full Year 2026 Financial Results and Provides Corporate Update

IRIXIRIDEX2026-03-26 20:05 EST

Iridex Reports Fourth Quarter and Full Year 2025 Financial Results

HYPRHyperfine2026-03-18 20:05 EST

Hyperfine, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

STIMNeuronetics2026-03-17 11:50 EST

Neuronetics Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

IRIXIRIDEX2026-03-12 20:05 EST

Iridex to Report Fourth Quarter and Full Year 2025 Financial Results on March 26, 2026

SGHTSight Sciences2026-05-06 20:05 EST

Sight Sciences Reports First Quarter 2026 Financial Results and Raises Full Year 2026 Revenue Guidance

PAVMPAVmed2026-05-14 12:00 EST

Lucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results

ICCMIceCure Medical2026-05-12 12:30 EST

IceCure Reports First Quarter 2026 Financial Results: ProSense® Sales Increase Substantially in the U.S. and North America

View all latest news

Xtant Medical

Xtant Medical is a spinal and biologics medical device company focused on bone grafts, biologics, and reconstructive products. Its business is centered on procedure-linked orthopedic care.

Recent company news

XTNTXtant Medical2026-05-13 11:00 EST

Xtant Medical Reports First Quarter 2026 Financial Results

XTNTXtant Medical2026-05-07 12:00 EST

Xtant Medical to Announce First Quarter 2026 Financial Results on May 13, 2026

XTNTXtant Medical2026-05-06 12:00 EST

Xtant Medical Expands Trivium™ Portfolio with the Commercial Launch of Trivium™ Shaped

XTNTXtant Medical2026-04-13 13:04 EST

Xtant Medical and Dilon Technologies Announce Exclusive U.S. Distribution Agreement for Dilon's HEMOBLAST® Bellows Product

XTNTXtant Medical2026-04-09 12:00 EST

Xtant Medical and Montana Governor's Office of Community Service Announce Support for "Threshold of Life" Memorial

Stock data

Close
0.44 USD
Market cap
65.22M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States